BSE filing, NSE: ERIS. Summary written from the filing by ALFA Finder's alert engine.
Eris Lifesciences Ltd: key numbers
- Share price
- ₹1,174.00
- Market cap
- ₹16,288 Cr
- Revenue (annual)
- ₹3,129 Cr
- Net profit (annual)
- ₹619.5 Cr
- P/E (TTM)
- 23.0×Sector 46.5×
- Promoter holding
- 54.74%+0.60% QoQ
- FII holding
- 5.74%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Eris Lifesciences Ltd
All →Eris Lifesciences Investor Presentation: Key Takeaways
Q2 FY27 consolidated revenue ₹892 Cr (+12.6%), PAT ₹187 Cr (+39.2%), EBITDA margin 34.7%. H1 PAT ₹330 Cr (+27.3%). Zorvia out-licensing supports DBF gross margin.
Eris Lifesciences Q2 FY27 Results: Net Profit ₹187.1 Cr, Up 39.1% YoY
Eris Lifesciences Ltd reported revenue from operations of ₹892.4 Cr (+12.6% YoY) and net profit of ₹187.1 Cr (+39.1% YoY) for Q2 FY27.
- Key figure
- Net profit ₹187.1 Cr · +39.1% YoY
Eris Lifesciences Other Announcement
Eris Lifesciences Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Eris Lifesciences Debt & Borrowing: ₹1,250 Cr
Eris Lifesciences Limited submitted its half-yearly reporting of debt securities for the period ended September 30, 2026. Two tranches of NCDs totaling ₹1,250 Crore remain outstanding.
- Value
- ₹1,250 Cr
Eris Lifesciences Management Change
Eris Lifesciences Limited announced the resignation of Mr. Krishnakumar Vaidyanathan from his roles as Executive Director and Chief Operating Officer. The resignation was effective September 30, 2026.
Eris Lifesciences Annual General Meeting
Eris Lifesciences Limited conducted its 20th Annual General Meeting on September 25, 2026. Shareholders transacted business including the adoption of audited financial statements and director re-appointments.
Other board meeting date announcements
All →Jetking Infotrain Board Meeting Date
Jetking Infotrain has scheduled a board meeting on November 4, 2026 to consider unaudited quarterly and half-year results. The trading window remains closed until 48 hours after the results announcement.
Metropolis Healthcare Board Meeting Date
Metropolis Healthcare intimated a board meeting on November 3, 2026 to consider Q2 and half-year unaudited results and possible interim dividend. Trading window is closed October 1 to November 5, 2026.
Aelea Commodities Board Meeting Date
Aelea Commodities has scheduled a board meeting for 2 November 2026 to consider half-year results and other items. The agenda includes an additional independent director, a director resignation, and business expansion and capex.
R Systems International Board Meeting Date
R Systems International will hold a board meeting on 3 November 2026 to consider quarterly and nine-month results to September 2026. The trading window remains closed until 48 hours after the results are declared.
Onida Electronics Board Meeting Date
Onida Electronics schedules a 3 November 2026 board meeting for Q2 and half-year results and ESOP share allotment. Trading window stays closed until 48 hours post-results.
Platinum Industries Board Meeting Date
Platinum Industries Ltd intimated a board meeting on November 4, 2026 to approve unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. Trading window closed from October 1, 2026.